Finance

Lists
Why is MESO down 9.45%?
Dive Deeper
MESO:NASDAQ
Mesoblast Ltd
$12.02
-9.45%
(-1.26) 1D
Oct 19, 12:59:44 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MESO...
Open
$12.48
High
$12.50
Low
$11.93
Mkt. cap
1.63B
Avg. vol.
230.78K
Volume
396.28K
52-wk high
$21.49
52-wk low
$11.93
EPS
-$0.44
Beta
2.14
Shares outstanding
130.13M
No. of employees
108
Open
$12.48
High
$12.50
Low
$11.93
Mkt. cap
1.63B
Avg. vol.
230.78K
Volume
396.28K
52-wk high
$21.49
52-wk low
$11.93
EPS
-$0.44
Beta
2.14
Shares outstanding
130.13M
No. of employees
108
News stories
From web sources and news partners
Profile
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004. Wikipedia
About Mesoblast Ltd
CEOSilviu Itescu
Employees108
Founded2004
Headquarters-
SectorBiotechnology
Websitemesoblast.com
Analyst ratings
Based on 2 analysts giving stock ratings to MESO in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for MESO in the last 3 months.
Highest
Current $12.02
$39.00 (+224.32%)
Average
$37.00 (+207.69%)
Lowest
$35.00 (+191.06%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason McCarthy
Maxim Group
Buy
Maintained
$35.00
+191.1%
09/24/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$39.00
+224.3%
08/27/2026
Last report
Jan 29, 2026
Fiscal period
Q2 2026
- / -A$0.03
Revenue / Est. (AUD)
42.92M / 34.76M
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
25.67M
25.67M
34.45M
34.45M
Cost of goods sold
26.88M
26.88M
-14.87M
-14.87M
Cost of revenue
26.88M
26.88M
-14.87M
-14.87M
Research and development expenses
-
-
45.07M
45.07M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.27M
14.27M
14.40M
14.40M
Operating expense
12.95M
12.95M
60.79M
60.79M
Total operating expenses
39.83M
39.83M
45.92M
45.92M
Operating income
-14.16M
-14.16M
-11.47M
-11.47M
Other non operating income
-4.16M
-4.16M
2.61M
2.61M
EBT including unusual items
-19.86M
-19.86M
-8.58M
-8.58M
EBT excluding unusual items
-23.68M
-23.68M
-10.94M
-10.94M
Income tax expense
222.50K
222.50K
84.00K
84.00K
Effective tax rate
-1.12%
-1.12%
-0.98%
-0.98%
Other operating expenses
-1.32M
-1.32M
1.31M
1.31M
Net income
-20.08M
-20.08M
-8.67M
-8.67M
Net profit margin
-78.22%
-78.22%
-25.16%
-25.16%
Earnings per share
-
-
-
-
Interest and investment income
-
-
1.96M
1.96M
Interest expense
-5.64M
-5.64M
-4.29M
-4.29M
Net interest expenses
-5.64M
-5.64M
-2.34M
-2.34M
Depreciation and amortization charges
-
-
-
-
EBITDA
-12.53M
-12.53M
-9.77M
-9.77M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps